Human Genome Sciences
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Human Genome Sciences sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Human Genome Sciences: 17 sponsored US clinical trials, none currently recruiting.
Human Genome Sciences sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 3 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Hepatitis C, with 1 trials.
Top-decile sponsor footprint
Human Genome Sciences ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Study of Belimumab Administered Subcutaneously to Healthy Subjects
NCT01583530
A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
NCT01013818
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
NCT00732940
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
NCT00708006
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
NCT00411385
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
NCT00583830
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
NCT00410384
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
NCT00402428
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT00315757
Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy
NCT00114699
A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01
NCT00583557
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
NCT00097435
Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
NCT00094848
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
NCT00071812
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
NCT00071487
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
NCT00657007
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
NCT00092924
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 9 |
| Phase 3 | 3 |
Therapeutic Areas
How the Human Genome Sciences early-phase archive is shaped
17 indexed studies, none listed as recruiting (0% open); 14 completed (82%).
Phase mix: 3 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Chronic Hepatitis C (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Human Genome Sciences: archived-pipeline peers nationwide
Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Human Genome Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 archived trials
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Human Genome Sciences page
17 registered trials is a research-attention snapshot, not an endorsement of Human Genome Sciences or any single study.
- None of Human Genome Sciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Chronic Hepatitis C is the condition Human Genome Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Hepatitis C trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Human Genome Sciences pipeline card: 17 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.